Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Unilever underlying sales grow in H1 despite lower turnover

(Sharecast News) - Consumer goods giant Unilever reported a 3.4% rise in underlying sales for H125, driven by balanced volume and price growth, despite turnover dipping 3.2% to €30.1bn due to adverse currency movements and disposals. Unilever's personal care unit led the charge with 4.8% growth, buoyed by strong performances from its Dove deodorants, while ice cream sales increased 5.9% ahead of its planned demerger in November.

Developed markets continued to outperform, up 4.3%, while emerging markets saw modest gains of 2.8%, with India showing signs of recovery and China and Indonesia expected to accelerate in H2.

Underlying operating profits, on the other hand, fell 4.8% to €5.8bn, with margins down 30bps to 19.3%, underlying earnings per share decreased 2.1% to €1.59 and free cash flow halved to €1.1bn, impacted by ice cream separation costs and higher working capital.

However, Unilever said it remains confident going forward, forecasting FY sales growth within its 3-5% range and margin improvements in H2.

CEO Fernando Fernandez said: "Our first half performance positions us well for the full year. In the second half, we expect further acceleration in emerging markets, particularly in Asia, and sustained momentum in developed markets.

"We are building a marketing and sales machine that drives desire at scale in our power brands and ensures execution excellence across all channels to deliver consistent volume growth and gross margin expansion."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.